Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

235.47 8.15 +3.59%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 62.6×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC (JAZZ) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a P/S ratio of 3.1×. Over the past ten years it has ranged from 1.5× (May 2025) to 9.6× (March 2015); the current reading is higher than 44% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/JAZZ/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Jazz Pharmaceuticals PLC P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/JAZZ/metrics/ps-ratio">Jazz Pharmaceuticals PLC (JAZZ) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	2.4×	29.79%
FY2024	1.9×	(10.67%)
FY2023	2.1×	(21.59%)
FY2022	2.7×	8.72%
FY2021	2.5×	(36.82%)
FY2020	3.9×	(0.72%)
FY2019	3.9×	(0.33%)
FY2018	3.9×	(22.82%)
FY2017	5.1×	12.41%
FY2016	4.5×	(30.24%)

Period	P/S ratio	Change
Sep 2026	3.2×	(4.08%)
Jun 2026	3.3×	25.54%
Mar 2026	2.6×	8.53%
Dec 2025	2.4×	26.24%
43 more quarters	Free account

Against its own ten years

Low 1.5× High 9.6×

Ten-year median 3.5×

Current reading's percentile 48

Company	P/S ratio
BMRN BioMarin Pharmaceutical Inc. compare	3.0×
JAZZ Jazz Pharmaceuticals PLC	3.1×
EXEL Exelixis, Inc. compare	6.8×
HALO Halozyme Therapeutics, Inc. compare	7.8×
TECH Bio-Techne Corp compare	9.3×
ASND Ascendis Pharma A/S compare	13.5×
BBIO BridgeBio Pharma, Inc. compare	15.5×
KYMR Kymera Therapeutics, Inc. compare	120×
SMMT Summit Therapeutics PLC compare	15,884×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Jazz Pharmaceuticals PLC (JAZZ) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on JAZZ

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on JAZZ

Stockrow Weekly